WO2005040402A3 - Diagnostics and therapeutics for diseases associated with n-acetylated alpha-linked acidic dipeptidase 2 (naaladase 2) - Google Patents

Diagnostics and therapeutics for diseases associated with n-acetylated alpha-linked acidic dipeptidase 2 (naaladase 2) Download PDF

Info

Publication number
WO2005040402A3
WO2005040402A3 PCT/EP2004/011402 EP2004011402W WO2005040402A3 WO 2005040402 A3 WO2005040402 A3 WO 2005040402A3 EP 2004011402 W EP2004011402 W EP 2004011402W WO 2005040402 A3 WO2005040402 A3 WO 2005040402A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
naaladase
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2004/011402
Other languages
French (fr)
Other versions
WO2005040402A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Stefanie Polej
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Stefanie Polej
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Stefanie Polej filed Critical Bayer Healthcare Ag
Priority to EP04790297A priority Critical patent/EP1678502A2/en
Priority to US10/575,362 priority patent/US20070099255A1/en
Publication of WO2005040402A2 publication Critical patent/WO2005040402A2/en
Publication of WO2005040402A3 publication Critical patent/WO2005040402A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a human NAALADASE 2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, neurologcial diseases, urological diseases, respiratory diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, neurological diseases, urological diseases, respiratory diseases and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of NAALADASE 2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/011402 2003-10-21 2004-10-12 Diagnostics and therapeutics for diseases associated with n-acetylated alpha-linked acidic dipeptidase 2 (naaladase 2) WO2005040402A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04790297A EP1678502A2 (en) 2003-10-21 2004-10-12 Diagnostics and therapeutics for diseases associated with n-acetylated alpha-linked acidic dipeptidase 2 (naaladase 2)
US10/575,362 US20070099255A1 (en) 2003-10-21 2004-10-12 Diagnostics and therapeutics for diseases associated with n-acetylated alpha-linked acidic dipeptidase 2(naaladase 2)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03023854.7 2003-10-21
EP03023854 2003-10-21

Publications (2)

Publication Number Publication Date
WO2005040402A2 WO2005040402A2 (en) 2005-05-06
WO2005040402A3 true WO2005040402A3 (en) 2005-09-01

Family

ID=34486086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011402 WO2005040402A2 (en) 2003-10-21 2004-10-12 Diagnostics and therapeutics for diseases associated with n-acetylated alpha-linked acidic dipeptidase 2 (naaladase 2)

Country Status (3)

Country Link
US (1) US20070099255A1 (en)
EP (1) EP1678502A2 (en)
WO (1) WO2005040402A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
GB201303308D0 (en) * 2013-02-25 2013-04-10 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004157A2 (en) * 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Cloning and characterisation of novel mammalian peptidases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004157A2 (en) * 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Cloning and characterisation of novel mammalian peptidases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JACKSON P F ET AL: "DESIGN OF NAALADASE INHIBITORS: A NOVEL NEUROPROTECTIVE STRATEGY", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 8, 2001, pages 949 - 957, XP009033678, ISSN: 0929-8673 *
PASSANI LUCIUS A ET AL: "N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer diseases", MOLECULAR AND CHEMICAL NEUROPATHOLOGY, vol. 31, no. 2, 1997, pages 97 - 118, XP000987254, ISSN: 1044-7393 *
ROSES ALLEN D ET AL: "Drug development and Alzheimer disease.", THE AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY : OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR GERIATRIC PSYCHIATRY. 2003 MAR-APR, vol. 11, no. 2, March 2003 (2003-03-01), pages 123 - 130, XP002326526, ISSN: 1064-7481 *

Also Published As

Publication number Publication date
EP1678502A2 (en) 2006-07-12
US20070099255A1 (en) 2007-05-03
WO2005040402A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2004042389A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2005075662A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2004097358A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
WO2005040402A3 (en) Diagnostics and therapeutics for diseases associated with n-acetylated alpha-linked acidic dipeptidase 2 (naaladase 2)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2004104595A3 (en) Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2005040792A3 (en) Diagnostics and therapeutics for diseases associated with arginyl aminopeptidase (aminopeptidase b)-like 1 (rnpepl1)
WO2005040795A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase-like 1 (npepli)
WO2004097034A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 4 (tmprss4)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2004098487A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 5 (tmprss5)
WO2005052587A3 (en) Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 7 (kcnk7)
WO2004106934A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
WO2005031359A3 (en) Diagnostics and therapeutics for diseases associated with arginyl aminopeptidase rnpep (rnpep)
WO2005040401A3 (en) Diagnostics and therapeutics for diseases associated with mosaic serine protease (msp)
WO2004071394A3 (en) Diagnostics and therapeutics for diseases associated with hm74
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004790297

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004790297

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007099255

Country of ref document: US

Ref document number: 10575362

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10575362

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004790297

Country of ref document: EP